Toshio Fujino, MD-Ph.D.

post-doctoral

Toshio joined the Hata Lab in April 2022. He received his MD at Nagoya City University, Japan and practiced as a thoracic surgeon in Japan, where he developed a great interest in cancer biology. He then obtained his Ph.D. at Kindai University, Japan, where he studied the resistance mechanism to MET-TKIs in lung cancer harboring MET exon 14 skipping mutation in the laboratory of Dr. Tetsuya Mitsudomi. Toshio is currently focusing on drug persister cancer cell and acquired resistance to targeted therapies especially in ALK-positive lung cancer. Despite of the initial drastic efficacy of molecular targeted therapy, all patients inevitably develop resistance. Toshio believes that his project will contribute to establish new treatment strategies for lung cancer to prevent the drug resistance.